Dipexium Pharmaceuticals Company Profile (NASDAQ:DPRX)

About Dipexium Pharmaceuticals

Dipexium Pharmaceuticals logoDipexium Pharmaceuticals, Inc. is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI). As a topical antibiotic, Locilex affects only the area to which it is applied, and does not spread to the entire body through the bloodstream, which is host to a number of different bacteria other than bacteria causing the skin infection. It is conducting over two Phase III clinical trials of Locilex for the treatment of Mild DFI (DPX-305 and DPX-306) in the United States. The Company has conducted over two separate Phase I skin irritation and skin sensitization studies. Locilex has demonstrated statistical non-inferiority to a systemic antibiotic in a randomized, active-controlled double blind, multi-center clinical study in patients with Mild or Moderate DFI.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: DPRX
  • CUSIP:
Key Metrics:
  • Previous Close: $1.25
  • 50 Day Moving Average: $1.40
  • 200 Day Moving Average: $6.16
  • 52-Week Range: $1.05 - $17.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.22
  • P/E Growth: -0.02
  • Market Cap: $13.34M
  • Outstanding Shares: 11,115,000
  • Beta: 2.25
Profitability:
  • Return on Equity: -104.73%
  • Return on Assets: -98.86%
Debt:
  • Current Ratio: 8.03%
  • Quick Ratio: 8.03%
Additional Links:
Companies Related to Dipexium Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Dipexium Pharmaceuticals (NASDAQ:DPRX) (?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $22.00 (1,733.33% upside)

Analysts' Ratings History for Dipexium Pharmaceuticals (NASDAQ:DPRX)
Show:
DateFirmActionRatingPrice TargetDetails
10/26/2016Raymond James Financial, Inc.DowngradeOutperform -> Mkt PerformView Rating Details
10/25/2016Feltl & Co.DowngradeBuy -> HoldView Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Dipexium Pharmaceuticals (NASDAQ:DPRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2017        
5/12/2016Q116($0.52)($0.56)ViewListenView Earnings Details
11/16/2015Q315($0.47)($0.49)ViewListenView Earnings Details
8/13/2015Q215($0.43)($0.47)ViewListenView Earnings Details
5/14/2015Q115($0.44)($0.49)ViewListenView Earnings Details
4/14/2015($0.44)($0.38)ViewN/AView Earnings Details
3/24/2015Q414$0.52($0.38)ViewN/AView Earnings Details
11/13/2014($0.49)($0.45)ViewN/AView Earnings Details
8/12/2014($0.37)($0.46)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dipexium Pharmaceuticals (NASDAQ:DPRX)
Current Year EPS Consensus Estimate: $-1.57 EPS
Next Year EPS Consensus Estimate: $-0.54 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.51)($0.51)($0.51)
Q3 20161($0.41)($0.41)($0.41)
Q4 20162($0.35)($0.35)($0.35)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dipexium Pharmaceuticals (NASDAQ:DPRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Dipexium Pharmaceuticals (NASDAQ:DPRX)
Insider Ownership Percentage: 47.70%
Institutional Ownership Percentage: 25.61%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/21/2014Jack H DeanDirectorBuy3,000$9.00$27,000.00View SEC Filing  
3/18/2014David GarrettVPBuy2,083$12.00$24,996.00View SEC Filing  
3/18/2014Thomas L HarrisonDirectorBuy2,000$12.00$24,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Dipexium Pharmaceuticals (NASDAQ:DPRX)
DateHeadline
News IconWatching the Technicals on Shares of Dipexium Pharmaceuticals Inc (DPRX) - The Standard (NASDAQ:DPRX)
6milestandard.com - February 24 at 10:29 PM
News IconDipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) Bending Lower ... - Aiken Advocate (NASDAQ:DPRX)
aikenadvocate.com - February 24 at 10:29 PM
bizjournals.com logoResearch Reports Coverage on Biotech Stocks -- Puma Biotechnology, Dipexium Pharma, BioCryst Pharma, and CTI BioPharma (NASDAQ:DPRX)
www.bizjournals.com - February 24 at 11:48 AM
finance.yahoo.com logoPLx Pharma Announces Publication of Positive Antiplatelet Data for Aspertec in Peer-Reviewed Medical Journal JACC (NASDAQ:DPRX)
finance.yahoo.com - February 14 at 5:39 PM
finance.yahoo.com logo7:31 am Dipexium Pharmaceuticals's PLx Pharma announces that the results of a 40-subject pharmacokinetic/pharmacodynamic (PK/PD) trial of Aspertec in Peer-Reviewed Medical Journal JACC (NASDAQ:DPRX)
finance.yahoo.com - February 14 at 5:39 PM
News IconIncrease in Volatility Draws Attention to Shares of Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) - Nelson Research (NASDAQ:DPRX)
nelsonobserver.com - February 2 at 5:13 PM
investornewswire.com logoDipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:DPRX)
www.investornewswire.com - January 31 at 5:05 AM
News IconEarnings in Full Force, Analysts Take Aim at Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) - Wall Street Beacon (NASDAQ:DPRX)
wsbeacon.com - January 26 at 6:03 PM
prnewswire.com logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Dipexium Pharma - DPRX - PR Newswire (press release) (NASDAQ:DPRX)
www.prnewswire.com - January 25 at 5:59 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Dipexium Pharma - DPRX (NASDAQ:DPRX)
finance.yahoo.com - January 25 at 5:59 PM
News IconPriming The Pump: Stock Volatility Spotted in Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) - Wall Street Beacon (NASDAQ:DPRX)
wsbeacon.com - January 24 at 3:08 AM
biz.yahoo.com logoDIPEXIUM PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report (NASDAQ:DPRX)
biz.yahoo.com - January 20 at 6:02 PM
News IconAre Discerning Investors Interested in These Shares: Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) - Prospect Journal (NASDAQ:DPRX)
prospectjournal.com - January 20 at 4:08 AM
News IconAre There Any Catalysts to Propel Shares of Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) - Prospect Journal (NASDAQ:DPRX)
prospectjournal.com - January 18 at 10:11 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) - Wall Street Beacon (NASDAQ:DPRX)
wsbeacon.com - January 16 at 9:48 PM
News IconWill The Needle Move For Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:DPRX)
wsbeacon.com - January 12 at 5:13 PM
News IconResearch Reports Initiation on Biotech Stocks -- ImmunoGen, BioMarin Pharma, CEL-SCI, and Dipexium Pharma (NASDAQ:DPRX)
www.kait8.com - January 9 at 4:42 PM
bizjournals.com logoHouston-based pharma company to merge with New York-based co. (NASDAQ:DPRX)
www.bizjournals.com - December 29 at 2:50 AM
News IconNew York-Based Dipexium to Merge with Privately-Held PLx Pharma Inc. (NASDAQ:DPRX)
www.biospace.com - December 29 at 2:50 AM
rttnews.com logoDipexium Pharmaceuticals Inc. (DPRX) Is Up Sharply After Merger Agreement (NASDAQ:DPRX)
www.rttnews.com - December 24 at 3:04 AM
feeds.benzinga.com logoMust Watch Stocks for December 23, 2016 (NASDAQ:DPRX)
feeds.benzinga.com - December 23 at 7:27 AM
us.rd.yahoo.com logo4:40 pm Dipexium Pharmaceuticals announces merger with PLx Pharma (shares halted) (NASDAQ:DPRX)
us.rd.yahoo.com - December 23 at 3:03 AM
streetinsider.com logoDipexium Pharma (DPRX) to Merge with PLx Pharma in All Stock Deal (NASDAQ:DPRX)
www.streetinsider.com - December 22 at 10:01 PM
marketwatch.com logoDipexium shares surge on announced merger with PLx Pharma (NASDAQ:DPRX)
www.marketwatch.com - December 22 at 10:01 PM
publicnow.com logoDipexium and PLx Pharma Announce Merger Agreement (NASDAQ:DPRX)
www.publicnow.com - December 22 at 5:00 PM
biz.yahoo.com logoDIPEXIUM PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Changes in Control or (NASDAQ:DPRX)
biz.yahoo.com - December 22 at 5:00 PM
News IconPacific Premier Bancorp Inc (NASDAQ:PPBI) showed P/E ratio of 24.03 (NASDAQ:DPRX)
www.xboxonezone.com - December 15 at 5:21 PM
biz.yahoo.com logoDIPEXIUM PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an (NASDAQ:DPRX)
biz.yahoo.com - December 14 at 5:50 PM
insidermonkey.com logoIs Dipexium Pharmaceuticals Inc (DPRX) A Good Stock To Buy? (NASDAQ:DPRX)
www.insidermonkey.com - December 14 at 3:29 AM
News IconPenny Stock Spotlight: Focusing on Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) - Duncan Research (NASDAQ:DPRX)
www.duncanindependent.com - November 23 at 10:20 PM
News IconWell recognized Stock of Market- Dipexium Pharmaceuticals, Inc.'s (DPRX) - Hot Stocks Point (NASDAQ:DPRX)
www.hotstockspoint.com - November 22 at 10:19 PM
News IconWonder Stock Alert: Investors Curious About Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) - Duncan Research (NASDAQ:DPRX)
www.duncanindependent.com - November 22 at 10:19 PM
finance.yahoo.com logoDIPEXIUM PHARMACEUTICALS, INC. Financials (NASDAQ:DPRX)
finance.yahoo.com - November 17 at 3:56 PM
biz.yahoo.com logoDIPEXIUM PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:DPRX)
biz.yahoo.com - November 16 at 4:46 PM
finance.yahoo.com logoDipexium Pharmaceuticals Reports Third Quarter 2016 Financial Results (NASDAQ:DPRX)
finance.yahoo.com - November 10 at 8:50 PM
sg.finance.yahoo.com logoDipexium Pharmaceuticals posts 3Q loss (NASDAQ:DPRX)
sg.finance.yahoo.com - November 10 at 1:14 PM
biz.yahoo.com logoDIPEXIUM PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:DPRX)
biz.yahoo.com - November 9 at 9:29 PM
News IconShares Knocked Down Over Past Month: Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) - CSZ News (NASDAQ:DPRX)
cincysportszone.com - November 5 at 4:45 PM
News IconPenny Stock Update: Looking At Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) - Duncan Research (NASDAQ:DPRX)
www.duncanindependent.com - November 4 at 9:40 PM
News IconDipexium Pharmaceuticals, Incorporated (NASDAQ:DPRX) predictive Earnings Analysis (NASDAQ:DPRX)
discover-usa.net - November 4 at 3:34 PM
News IconPenny Stock in the News: Focusing In On Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) - Duncan Research (NASDAQ:DPRX)
www.duncanindependent.com - November 3 at 4:20 PM
News IconNewsmaking Penny Stock: Update on Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) - Duncan Research (NASDAQ:DPRX)
www.duncanindependent.com - November 2 at 4:49 PM
News IconStock Feeling Some Pressure as It Experiences a Gap Down: Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) - CSZ News (NASDAQ:DPRX)
cincysportszone.com - November 2 at 6:30 AM
News IconNewsworthy Penny Stock: Investors Checking In On Dipexium Pharmaceuticals, Inc. (NASDAQ:DPRX) - Duncan Research (NASDAQ:DPRX)
www.duncanindependent.com - November 2 at 6:30 AM
biz.yahoo.com logoDIPEXIUM PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:DPRX)
biz.yahoo.com - October 31 at 4:46 PM
News IconDipexium Pharmaceuticals Inc (NASDAQ:DPRX) Could Recover Quicker Than Markets Think (NASDAQ:DPRX)
streetregister.com - October 29 at 4:36 PM
News IconCorgan Wrestles For TNA Control (NASDAQ:DPRX)
istreetresearch.com - October 28 at 4:27 PM
finance.yahoo.com logoDipexium Pharmaceuticals downgraded by Raymond James (NASDAQ:DPRX)
finance.yahoo.com - October 26 at 4:44 PM
finance.yahoo.com logoBlog Coverage Dipexium Stock Tanks on Trial Failure (NASDAQ:DPRX)
finance.yahoo.com - October 26 at 4:44 PM
fxpips.com logoStocks Making Gaps Down – JNP, PMBC, CALA, FCEL, CRBP, SONC, SPN (NASDAQ:DPRX)
www.fxpips.com - October 26 at 7:11 AM

Social

What is Dipexium Pharmaceuticals' stock symbol?

Dipexium Pharmaceuticals trades on the NASDAQ under the ticker symbol "DPRX."

Where is Dipexium Pharmaceuticals' stock going? Where will Dipexium Pharmaceuticals' stock price be in 2017?

1 equities research analysts have issued 12-month price targets for Dipexium Pharmaceuticals' shares. Their predictions range from $22.00 to $22.00. On average, they expect Dipexium Pharmaceuticals' share price to reach $22.00 in the next year.

When will Dipexium Pharmaceuticals announce their earnings?

Dipexium Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March, 21st 2017.

How do I buy Dipexium Pharmaceuticals stock?

Shares of Dipexium Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Dipexium Pharmaceuticals stock cost?

One share of Dipexium Pharmaceuticals stock can currently be purchased for approximately $1.20.

Dipexium Pharmaceuticals (NASDAQ:DPRX) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Dipexium Pharmaceuticals (NASDAQ:DPRX)

Earnings History Chart

Earnings by Quarter for Dipexium Pharmaceuticals (NASDAQ:DPRX)

Dividend History Chart

Dividend Payments by Quarter for Dipexium Pharmaceuticals (NASDAQ:DPRX)

Last Updated on 2/25/2017 by MarketBeat.com Staff